Related Experiment Videos
Hyperhomocysteinemia and atherothrombotic disease
S C de Jong1, M van den Berg, J A Rauwerda
1Institute for Cardiovascular Research, Vrije Universiteit, Amsterdam, The Netherlands.
Seminars in Thrombosis and Hemostasis
|October 8, 1998
Summary
High homocysteine levels (hyperhomocysteinemia) contribute to vascular disease. Understanding how homocysteine damages blood vessels is crucial for developing effective treatments for atherothrombotic conditions.
Area of Science:
- Cardiovascular Science
- Vascular Biology
- Metabolic Disorders
Background:
- Hyperhomocysteinemia is a known risk factor for atherothrombotic diseases.
- The precise mechanisms linking homocysteine to atherosclerosis and thrombosis remain unclear.
- Limited human data exist on arterial histology in homocystinuria and mild hyperhomocysteinemia.
Purpose of the Study:
- To investigate the impact of hyperhomocysteinemia on vascular endothelium function and smooth muscle cell proliferation.
- To explore the role of homocysteine in atherogenesis and thrombosis.
- To assess endothelial dysfunction in hyperhomocysteinemic patients and healthy individuals.
Main Methods:
- Review of in vitro, animal, and human studies on hyperhomocysteinemia.
- Analysis of endothelial function (vasodilation, antithrombotic properties) in hyperhomocysteinemic subjects.
- Examination of vascular smooth muscle cell proliferation.
Main Results:
- Hyperhomocysteinemia induces vascular endothelial dysfunction, impairing vasodilation and antithrombotic properties.
- Endothelial antithrombotic properties are more severely impaired in hyperhomocysteinemic vascular patients compared to normohomocysteinemic patients.
- Clinically healthy hyperhomocysteinemic subjects show impaired endothelium-dependent vasodilation but normal endothelial antithrombotic properties.
Conclusions:
- Hyperhomocysteinemia significantly contributes to atherothrombotic disease through endothelial dysfunction and smooth muscle cell proliferation.
- Oxidative damage is a potential mechanism requiring further human investigation.
- Homocysteine-lowering therapies warrant further study in both vascular patients and healthy individuals to elucidate causal mechanisms.